efavirenz has been researched along with Behavior Disorders in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (50.00) | 29.6817 |
| 2010's | 14 (46.67) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Butler, LT; Hamill, MM; Law, JKC | 1 |
| Belcher, R; Marcangelo, M | 1 |
| Ahrens, J; Drury, A; Gilfillan, S; Gleadow-Ware, S | 1 |
| Aklillu, E; Aris, E; Bakari, M; Bertilsson, L; Burhenne, J; Janabi, M; Minzi, O; Mugusi, F; Mugusi, S; Ngaimisi, E; Sandstrom, E | 1 |
| Arinaitwe, WJ; Khoo, S; Kiiza, D; Laker, E; Lamorde, M; Seden, K; Waitt, C | 1 |
| Larsen, CS; Leutscher, PD; Stecher, C; Storgaard, M | 1 |
| Akhondzadeh, S; Alimadadi, A; Dabaghzadeh, F; Ghaeli, P; Jafari, S; Khalili, H; Khazaeipour, Z | 1 |
| Aklillu, E; Gustafsson, LL; Luzze, H; Mukonzo, JK; Nakasujja, N; Ogwal-Okeng, J; Okwera, A; Sebuwufu, D; Waako, P | 1 |
| Currán, A; Deig, E; Guardiola, JM; Guelar, A; Llibre, JM; Martínez-Madrid, O; Pedrol, E; Ramírez, R; Tasias, M; Tikhomirova, L | 1 |
| Bisaso, KR; Ette, EI; Mukonzo, JK | 1 |
| Dandara, C; Leutscher, PD; Masimirembwa, C | 1 |
| Casado, JL; Corral, I; Dronda, F; Hernández, B; Moreno, A; Moreno, S; Pérez-Elías, MJ; Quereda, C; Rodríguez-Sagrado, MA | 1 |
| Gutiérrez-Valencia, A; López-Cortés, LF; Lozano, F; Palacios, R; Rivero, A; Ruiz-Valderas, R; Terrón, A; Viciana, P | 1 |
| Gauggel, S; Sütterlin, S; Vögele, C | 1 |
| Goforth, HW; Kenedi, CA | 1 |
| Castagna, A; Duvivier, C; Gazzard, B; Hill, A; Marks, S; van Delft, Y; Zagler, C | 1 |
| Antinori, A; Boven, K; Clotet, B; Fourie, J; Herrera, G; Hicks, C; Madruga, JV; Mills, AM; Stevens, M; Vanveggel, S | 1 |
| Puzantian, T | 1 |
| Delmas, B; Lochet, P; Lotthé, A; Mauboussin, JM; Peyrière, H; Reynes, J | 1 |
| Fulgaro, C; Rosticelli, E; Sabbatani, S | 1 |
| Bary, M; David, F; Gasnault, J; Kerneis, H; Linard, F; Longuet, P; Pelissolo, A; Ravaux, I | 1 |
| Baraldi, E; Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Montella, F; Robinson, PA; Russell, DB; Thompson, MA; Uip, DE; van Leth, F | 1 |
| Dawson, S; Woods, C | 1 |
| Best, B; Capparelli, E; Goicoechea, M; Haubrich, R | 1 |
| Curtin, JM; Ward, DJ | 1 |
| Begley, K; Callaghan, A; Gold, J; Kelly, M; Post, JJ; Rihs, TA; Sarangapany, J; Smith, DE | 1 |
| Arendt, G; de Nocker, D; Nolting, T; von Giesen, HJ | 1 |
| Boyle, BA; Goldenberg, D | 1 |
| Fabre, J; Hillaire-Buys, D; Mauboussin, JM; Peyriere, H; Reynes, J; Rouanet, I | 1 |
7 review(s) available for efavirenz and Behavior Disorders
| Article | Year |
|---|---|
HIV and mental illness in Malawi and the neuropsychiatric sequelae of efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Mental Disorders | 2018 |
Rolling out Efavirenz for HIV Precision Medicine in Africa: Are We Ready for Pharmacovigilance and Tackling Neuropsychiatric Adverse Effects?
Topics: Africa South of the Sahara; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Drug Monitoring; Drug Resistance, Viral; HIV Infections; Humans; Mental Disorders; Patient Compliance; Pharmacogenomic Variants; Precision Medicine; Quality of Life | 2016 |
Neuropsychiatric complications of efavirenz therapy: suggestions for a new research paradigm.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Biomedical Research; Cyclopropanes; HIV Infections; Humans; Mental Disorders; Models, Biological; Psychophysiology | 2010 |
A systematic review of the psychiatric side-effects of efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Mental Disorders; Sleep Initiation and Maintenance Disorders | 2011 |
Central nervous system adverse effects with efavirenz: case report and review.
Topics: AIDS Dementia Complex; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Humans; Male; Mental Disorders; Middle Aged; Oxazines | 2002 |
[Neurospychiatric symptoms in HIV infected patients and the role of efavirenz].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Incidence; Mental Disorders; Oxazines | 2004 |
Neuropsychiatric side effects of efavirenz therapy.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Humans; Mental Disorders; Neuropsychological Tests; Nevirapine; Oxazines | 2007 |
5 trial(s) available for efavirenz and Behavior Disorders
| Article | Year |
|---|---|
Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cyproheptadine; Depression; Double-Blind Method; Female; HIV Infections; Humans; Iran; Male; Mental Disorders; Personality Inventory; Psychiatric Status Rating Scales; Serotonin Antagonists; Socioeconomic Factors; Suicidal Ideation; Surveys and Questionnaires; Treatment Outcome | 2013 |
Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV-coinfected patients.
Topics: Alkynes; Anti-HIV Agents; Anxiety Disorders; Benzoxazines; Cyclopropanes; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Mental Disorders; Mood Disorders | 2008 |
Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Mental Disorders; Middle Aged; Reverse Transcriptase Inhibitors; Sample Size; Sleep Wake Disorders; Viral Load | 2009 |
Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.
Topics: Adolescent; Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; Humans; Male; Mental Disorders; Middle Aged; Nervous System Diseases; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2011 |
Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Mental Disorders; Middle Aged; Nervous System Diseases; Nitriles; Pyrimidines; Rilpivirine; Viral Load; Young Adult | 2013 |
18 other study(ies) available for efavirenz and Behavior Disorders
| Article | Year |
|---|---|
Predictors of Discontinuation of Efavirenz as Treatment for HIV, Due to Neuropsychiatric Side Effects, in a Multi-Ethnic Sample in the United Kingdom.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Ethnicity; Female; HIV Infections; Humans; Male; Mental Disorders; Middle Aged; Retrospective Studies; Treatment Adherence and Compliance; United Kingdom; Withholding Treatment; Young Adult | 2020 |
Efavirenz precipitating hallucinations in a patient with an undetected psychotic prodrome: a call for better screening at the point of care.
Topics: Adult; Alkynes; Antipsychotic Agents; Benzoxazines; Cyclopropanes; Hallucinations; HIV Infections; Humans; Male; Mental Disorders; Point-of-Care Systems | 2017 |
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
Topics: Adult; Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Mental Disorders; Pharmacogenetics; Prospective Studies; Rifampin; Tuberculosis | 2018 |
High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dizziness; Drug Administration Schedule; Female; HIV Infections; Humans; Longitudinal Studies; Male; Mental Disorders; Nervous System Diseases; Outpatients; Prevalence; Prospective Studies; Risk Factors; Uganda | 2018 |
Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Mental Disorders; Withholding Treatment | 2013 |
Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cognitive Dysfunction; Constitutive Androstane Receptor; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Female; Gene Frequency; Hallucinations; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Memory Disorders; Mental Disorders; Prospective Studies; Rifampin; Sleep Arousal Disorders; Tuberculosis; Uganda | 2013 |
Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System Diseases; Cyclopropanes; Drug Substitution; Female; HIV Infections; Humans; Male; Medication Adherence; Mental Disorders; Middle Aged; Nevirapine; Prospective Studies; Quality of Life; Reverse Transcriptase Inhibitors | 2015 |
Transition modeling of neuropsychiatric impairment in HIV.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Mental Disorders; Models, Psychological; Time Factors | 2016 |
Comparison of side effects with 2 doses of the HIV drug efavirenz.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Mental Disorders; Middle Aged; Sample Size; Sleep Wake Disorders; Viral Load | 2009 |
Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Anxiety Disorders; Benzoxazines; Cognition Disorders; Cyclopropanes; Depressive Disorder; Female; Follow-Up Studies; HIV Infections; Humans; Male; Mental Disorders; Middle Aged; Mood Disorders; Oxazines; Quality of Life; Sleep Wake Disorders; Surveys and Questionnaires | 2003 |
[Efficacy of efavirenz in a mixed population of patients. Identification of drop-out causes].
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Eruptions; Drug Evaluation; Female; HIV Infections; Humans; Male; Mental Disorders; Middle Aged; Oxazines; Patient Dropouts; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2002 |
Are adverse events of nevirapine and efavirenz related to plasma concentrations?
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Chemical and Drug Induced Liver Injury; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Exanthema; Female; HIV Infections; Humans; Male; Mental Disorders; Middle Aged; Nevirapine; Odds Ratio; Oxazines | 2005 |
Neuropsychiatric effects of efavirenz: delayed onset.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Mental Disorders; Oxazines; Reverse Transcriptase Inhibitors; Time Factors | 2005 |
Concurrent use of efavirenz and oxcarbazepine may not affect efavirenz plasma concentrations.
Topics: Adult; Alkynes; Anti-HIV Agents; Anticonvulsants; Benzoxazines; Bipolar Disorder; Carbamazepine; Cyclopropanes; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Monitoring; HIV Infections; Humans; Male; Mental Disorders; Nervous System Diseases; Oxazines; Oxcarbazepine; Treatment Failure; Viral Load | 2006 |
Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Dyslipidemias; Female; HIV Infections; Humans; Lipids; Male; Mental Disorders; Middle Aged; Nevirapine; Oxazines; Retrospective Studies; Reverse Transcriptase Inhibitors | 2006 |
Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study.
Topics: Adult; Alkynes; Australia; Behavioral Symptoms; Benzoxazines; Case-Control Studies; Cross-Sectional Studies; Cyclopropanes; Dreams; Female; HIV Infections; Humans; Male; Mental Disorders; Neuropsychological Tests; Prevalence; Reverse Transcriptase Inhibitors; Self Disclosure; Stress, Psychological | 2006 |
Current issues in antiretroviral and psychiatric therapy for HIV-infected patients.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Mental Disorders; Oxazines; Pneumonia, Pneumocystis; Viremia | 2000 |
Management of sudden psychiatric disorders related to efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Mental Disorders; Oxazines; Reverse Transcriptase Inhibitors | 2001 |